Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy

Clinical Microbiology and Infection

Volumn 17, Issue 7, 2011, Pages 1078-1083

  Suppli, M ^a   Aabenhus, R ^a   Harboe, Z B ^a,c   Andersen, L P ^a   Tvede, M ^a   Jensen, J U S ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

Antibiotics; Bacteraemia; Co morbidity; Enterococcus; Enterococcus faecalis; Enterococcus faecium; Mortality

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; BETA LACTAM; LINEZOLID; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIAL GROWTH; BLOODSTREAM INFECTION; CHRONIC DISEASE; DENMARK; ENDOCARDITIS; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; HUMAN; IN VITRO STUDY; INAPPROPRIATE PRESCRIBING; INTENSIVE CARE UNIT; LIVER FAILURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; TERTIARY HEALTH CARE; THROMBOCYTOPENIA;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM;

EID: 79959991759     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03394.x     Document Type: Article

References (23)

1. Alberti C, Brun-Buisson C, Burchardi H et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002; 28: 108-121.
2. National Nosocomial Infections Surveillance (NNIS). System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999; 27: 520-532.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
4. Schonheyder HC, Sogaard M. Hospital-acquired bacteraemia and fungaemia. A regional study with national implications. Ugeskr Laeger 2007; 169: 4175-4179.
5. Bar K, Wisplinghoff H, Wenzel RP, Bearman GM, Edmond MB. Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infections due to enterococci. BMC Infect Dis 2006; 6: 145.
6. Patterson JE, Sweeney AH, Simms M et al. An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome. Medicine (Baltimore) 1995; 74: 191-200.
7. Linden PK, Miller CB. Vancomycin-resistant enterococci: the clinical effect of a common nosocomial pathogen. Diagn Microbiol Infect Dis 1999; 33: 113-120.
8. Landry SL, Kaiser DL, Wenzel RP. Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: a controlled study. Am J Infect Control 1989; 17: 323-329.
9. Hoge CW, Adams J, Buchanan B, Sears SD. Enterococcal bacteremia: to treat or not to treat, a reappraisal. Rev Infect Dis 1991; 13: 600-605.
10. Anderson DJ, Murdoch DR, Sexton DJ et al. Risk factors for infective endocarditis in patients with enterococcal bacteremia: a case-control study. Infection 2004; 32: 72-77.
11. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244: 379-386.
12. Bryan CS, Reynolds KL, Brown JJ. Mortality associated with enterococcal bacteremia. Surg Gynecol Obstet 1985; 160: 557-561.
13. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999; 20: 318-323.
14. Vergis EN, Hayden MK, Chow JW et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 2001; 135: 484-492.
15. Vergis EN, Shankar N, Chow JW et al. Association between the presence of enterococcal virulence factors gelatinase, hemolysin, and enterococcal surface protein and mortality among patients with bacteremia due to Enterococcus faecalis. Clin Infect Dis 2002; 35: 570-575.
16. Teixeira LM, Carvalho MGS, Facklam RR. Enterococcus. In: Murray P, Baron EJ, Jorgensen J, Pfaller M, Landry ML, eds, Manual of clinical microbiology. Washington DC: ASM Press, 2007; 470-481.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
18. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992; 101: 1481-1483.
19. Hsieh FY, Lavori PW, Cohen HJ, Feussner JR. An overview of variance inflation factors for sample-size calculation. Eval Health Prof 2003; 26: 239-257.
20. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials 2000; 21: 552-560.
21. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-155.
22. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474.
23. Freundlich M, Thomsen RW, Pedersen L, West H, Schonheyder HC. Aminoglycosides therapy in patients with bacteraemia. Ugeskr Laeger 2008; 170: 457-460.